For example, HA-based nanocarriers have been developed to improve drug delivery efficiency and reduce off-target accumulation [28]; however, these HA-based compounds could trigger CD44 signalling pathways in cancer cells, leading to unintended consequences such as the promotion of tumor growth, invasion, or metastasis. The gene discussed is CD44; the disease is cancer.